PD-L1 antibody
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for PD-L1 antibody, covering 2024-12-19 to 2025-10-06. Get the full timeline:
Most recent: Clinical Trial Update: AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer. [Phase 2]